| Date | Title | Description |
| 16.09.2026 | Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors | - |
| 10.09.2026 | Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program | - |
| 28.07.2026 | Alkermes plc Reports Second Quarter 2026 Financial Results | Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended June 30, 2026. To view the detailed second quarter 2026 earnings press release and presentation, please visit the company’s investor relations website at htt... |
| 17.06.2026 | Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026 | Alkermes plc (Nasdaq: ALKS) today announced detailed positive results from the Vibrance-2 phase 2 dose-ranging study evaluating alixorexton in patients with narcolepsy type 2 (NT2). Once-daily alixorexton met the study’s dual primary endpoi... |
| 15.06.2026 | Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe | Alkermes plc (Nasdaq: ALKS) today announced that alixorexton, a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hyp... |
| 04.06.2026 | Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research | Alkermes plc (Nasdaq: ALKS) today announced plans to present new data from its industry-leading portfolio of sleep medicine research at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), taking place ... |
| 03.06.2026 | Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference | Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Wednesday, June 10, 2026 at 10:00 a.m. ET (3:00 p.m. BST). The live webcast may... |
| 26.05.2026 | Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting | Alkermes plc (Nasdaq: ALKS) today announced plans to present clinical and real-world data related to the company’s psychiatry and orexin portfolios at the American Society of Clinical Psychopharmacology Annual Meeting, taking place May 26-2... |
| 21.05.2026 | Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences | Alkermes plc (Nasdaq: ALKS) today announced the presentation of accepted research at key scientific conferences this spring related to its psychiatry products—LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil)—and i... |
| 12.05.2026 | Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia | Alkermes plc (Nasdaq: ALKS) today announced positive topline results from the REVITALYZ℠ double-blind, placebo-controlled, randomized withdrawal, multicenter phase 3 study evaluating the investigational use of LUMRYZ® (sodium oxybate) exten... |
| 05.05.2026 | Alkermes plc Reports First Quarter 2026 Financial Results | Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended March 31, 2026 and financial expectations for full year 2026. To view the detailed first quarter 2026 earnings press release and presentation, please visit t... |
| 03.04.2026 | Lilly покупает британского разработчика лекарства от расстройства сна за $7,8 млрд | Препарат Zepbound компании Eli Lilly & Co. помогает решать одну из самых сложных проблем здравоохранения нашего времени — ожирение. Теперь фармкомпания берется за еще одну серьезную проблему общественного здоровья: расстройства сна.
В с... |
| 01.04.2026 | Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2 | Alkermes plc (Nasdaq: ALKS) today announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2)... |
| 12.03.2026 | Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program | Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its inaugural Alkermes Pathways APN Research Awards™ program on Monday, March 16, 2026. This competitive grant program is designed to support research... |
| 25.02.2026 | Alkermes plc Announces CEO Succession Plan | Alkermes plc (Nasdaq: ALKS) (Alkermes) today announced that Richard Pops will retire from his role as Chief Executive Officer (CEO), effective July 31, 2026. Alkermes’ Board of Directors (the Board) appointed Blair Jackson, Alkermes’ curren... |
| 25.02.2026 | Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026 | Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2025 and provided financial expectations for 2026. To view the detailed fourth quarter and full year 2025 earnings press release and presen... |
| 24.02.2026 | Alkermes to Present at the TD Cowen 46th Annual Health Care Conference | Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 9:10 a.m. ET (2:10 p.m. GMT). The live webcast may be accessed un... |
| 11.02.2026 | Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026 | Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Wednesday, Feb. 25, 2026 to discuss the company’s fourth quarter and year-end 2025 financial results. Management will also d... |
| 16.01.2026 |
Cramer’s Lightning Round: Sell Super Micro Computer | Monday - Friday, 6:00 - 7:00 PM ET
It’s that time again! “Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at rapid speed.
Super Micro Computer: “Sell. I don’t need t... |
| 31.12.2025 | M&A deals won’t break 2024 record | Last year’s megadeals meant 2025 had a tough act to follow. Gerry Byrne finds that while transactions are at a similar level to 2024, the value of M&A activity in the last 12 months is unlikely to reach the same peak
Despite the number ... |
| 30.12.2025 | Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference | Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 44th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Tuesday, Jan.... |
| 13.11.2025 | Nasdaq closes higher, snapping three-day losing streak as tech stocks recover some ground | The Nasdaq Composite rebounded on Friday as investors bought up shares of key technology stocks a day after the group led Wall Street to its worst day in more than a month.
The tech-heavy Nasdaq gained 0.13% to finish at 22,900.59, snapping... |
| 11.11.2025 | Dow rallies 400 points to new record with shutdown set to end Wednesday: Live updates | The Dow Jones Industrial Average rose to new heights on Wednesday, extending its gains from the previous session, as Wall Street looks ahead to a potential end to the record-breaking U.S. government shutdown.
The 30-stock Dow was last up 42... |
| 23.10.2025 | Ирландская Alkermes покупает американского производителя лекарств от бессонницы Avadel за $2,1 млрд | Сделка открывает для Alkermes доступ на рынок медицины сна благодаря препарату Lumryz компании Avadel, одобренному для лечения катаплексии или чрезмерной дневной сонливости у пациентов от семи лет и старше, страдающих нарколепсией — заболев... |
| 08.07.2025 | Narcolepsy Network Announces its 38th Annual Conference | A Weekend of Learning, Community and Hope
CAMAS, Wash., July 8, 2025 /PRNewswire-PRWeb/ -- Narcolepsy Network is delighted to announce its 38th Annual Conference, taking place Friday, October 24 through Sunday, October 26, 2025, at the Roya... |
| 24.11.2024 | Navigating the Sleep Science Frontier: A New Era for Hypersomnolence Treatment | Sleep is a complex puzzle. For many, it’s a sanctuary. For others, it’s a battleground. Central disorders of hypersomnolence, like narcolepsy and idiopathic hypersomnia, turn sleep into a foe. These conditions cause excessive daytime sleepi... |
| 18.11.2024 | State-of-the-science webinar will explore narcolepsy and hypersomnia | Sleep Research Society Foundation
Free webinar from the Sleep Research Society Foundation is Monday, Dec. 2.
DARIEN, Ill., Nov. 18, 2024 /PRNewswire-PRWeb/ -- The Sleep Research Society Foundation is hosting a state-of-the-science webinar, ... |
| 13.06.2024 | Global Gene's RARE-X and Sleep Consortium Launch Sleep Data Collection Initiative to Accelerate Development of Therapies | Global Genes
The Sleep Data Collection Initiative, the first consortium on the RARE-X platform for the collection and sharing of patient-owned data, brings together patient advocacy organizations, researchers, and drug developers looking to... |
| 12.03.2024 | Opioid Use Disorder Market to Reach USD 6.15 Billion by 2030, Driven by Growing Focus on Addiction Treatment | Opioid Use Disorder (OUD) Market
Opioid Use Disorder Market Analysis, Industry Trends and Growth Outlook AUSTIN, TEXAS, UNITED STATES, March 12, 2024 /EINPresswire.com/ -- The global opioid use disorder market is experiencing significant gr... |
| 16.10.2023 | How is Revolutionary Biotech Transforming Chronic Disease Treatment in Healthcare? | Key Takeaways:
Alkermes is a Dublin-based biotech startup that develops, manufactures, and commercializes pharmaceuticals that treat chronic diseases.
The company’s pipeline includes extended-release injectable and oral products formed to a... |
| 08.05.2023 | Alkermes Files Preliminary Proxy Statement and Provides Update on Annual Director Nomination Process | DUBLIN, May 8, 2023 /PRNewswire/ -- Alkermes plc ALKS today filed its preliminary proxy statement with the U.S. Securities and Exchange Commission (SEC) in connection with its upcoming Annual General Meeting of Shareholders (the Annual Meet... |
| 03.05.2023 | WCVB Channel 5 Chronicle Reporter and Producer Nicole Estaphan to Emcee Melanoma Research Foundation’s Miles for Melanoma 5K | BOSTON (PRWEB) May 03, 2023
The Melanoma Research Foundation (MRF) is thrilled to announce that WCVB Channel 5 Chronicle Reporter and Producer Nicole Estaphan will be returning as the event emcee for the annual Miles for Melanoma New Englan... |
| 06.01.2022 | New National Survey of People Living with Bipolar I Disorder Provides Insights Into Disease-Related Challenges and the Treatment Journey | DUBLIN, Jan. 6, 2022 /PRNewswire/ -- Results from a newly released survey provide insights from adults living with bipolar I disorder (BD-I)* in the United States (U.S.) on the burden of living with this serious mental health condition and ... |
| 27.10.2021 | Q3 2021 Earnings slides 10 26 21 FINAL_v3.pdf | Third Quarter 2021
Financial Results & Business Update
October 27, 2021
© 2021 Alkermes. All rights reserved.
Forward-Looking Statements and Non-GAAP Financial Information
Certain statements set forth in this presentation constitute &qu... |
| 09.09.2021 | Alkermes Announces Launch of 4th Annual Alkermes Pathways Research Awards® Program | |
| 02.08.2021 | Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma | |
| 28.07.2021 | Alkermes plc Reports Second Quarter 2021 Financial Results
USA - English France - Français España - español Latin America - español USA - English | |
| 26.07.2021 | Alkermes : Announces Recipients of 2021 Alkermes Inspiration Grants Program | DUBLIN - Alkermes plc (Nasdaq: ALKS) announced the 2021 recipients of grants from the company's signature Alkermes Inspiration Grants program. Grants were awarded to 11 nonprofit organizations working to address the needs of people living w... |
| 23.07.2021 | Alkermes Announces Recipients of 2021 Alkermes Inspiration Grants® Program | |
| 01.06.2021 | Alkermes Announces FDA Approval of LYBALVI™ for the Treatment of Schizophrenia and Bipolar I Disorder | |
| 20.05.2021 | Alkermes Announces the Appointment of Emily Peterson Alva to its Board of Directors | |
| 14.05.2021 | ALKERMES PLC
Alkermes : Announces 2021 Alkermes Inspiration Grants Program to Support Innovative Programs Focused on People Affected by Addiction, Serious Mental Illness or Cancer | DUBLIN - Alkermes plc (Nasdaq: ALKS) announced that the company will begin accepting applications for its Alkermes Inspiration Grants program beginning on May 20, 2021. Now in its fifth year, this competitive grants program will provide up ... |
| 13.05.2021 | Alkermes Announces 2021 Alkermes Inspiration Grants® Program to Support Innovative Programs Focused on People Affected by Addiction, Serious Mental Illness or Cancer | |
| 03.05.2021 | Alkermes to Showcase Data From Psychiatry Portfolio at Upcoming Scientific Conferences Throughout Mental Health Awareness Month | |
| 30.04.2021 | Alkermes Announces Agreement with Sarissa Capital | |
| 28.04.2021 | Alkermes Announces Two Abstracts Accepted for Presentation at 2021 American Society of Clinical Oncology Annual Meeting | |
| 27.04.2021 | Alkermes Launches New Disease State Website to Offer Education About Alcohol Dependence | |
| 07.04.2021 | Alkermes Announces Clinical Trial Collaboration and Supply Agreement With MSD to Evaluate Nemvaleukin Alfa in Combination With KEYTRUDA® in Patients With Platinum-Resistant Ovarian Cancer | |
| 11.02.2021 | Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2020 and Provides Financial Expectations for 2021 | |
| 06.01.2021 | Alkermes Announces Updates to Executive Leadership Team | |
| 10.12.2020 | Alkermes Announces Strategic Value Enhancement Plan and Continued Board Refreshment | |
| 17.11.2020 | Alkermes Receives FDA Complete Response Letter Related to ALKS 3831 Manufacturing Records Review | |
| 29.10.2020 | Alkermes plc Reports Third Quarter 2020 Financial Results and Raises 2020 Financial Expectations | |
| 02.11.2018 | FDA AdCom smacks down Alkermes antidepressant drug, making approval unlikely | Briefing documents released earlier this week, prior to the AdCom meeting, had already cast doubt on PDAC’s sentiments toward the drug, raising concerns about safety and efficacy, as well as criticism of the use of an abbreviated scoring sy... |
| 03.02.2015 | Veteran reporter Luke Timmerman is back – and launching his own biotech news site | Luke Timmerman’s gone rogue.
The veteran life sciences reporter, who left Xconomy last year, is back to day-to-day journalism. Except this time, he’s doing it on his own: Timmerman just launched his own biotech site – The Timmerman Report –... |
| - | FDA AdCom smacks down Alkermes antidepressant drug, making approval unlikely | A Food and Drug Administration expert panel has declined to endorse an opioid-based antidepressant drug, putting its chances for approval in jeopardy.
The FDA’s Psychopharmacologic Drugs Advisory Committee voted 21-to-2 that the risk-benefi... |
| - | A new era for neuroscience and oncology drug development: The biopharma driving R&D innovation | Among the most incredible achievements of humankind over the last few decades are the indisputable advancements in medical science — remarkable treatments that contribute to longer, healthier lives worldwide. Yet, despite awe-inspiring inno... |
| - | Veteran reporter Luke Timmerman is back – and launching his own biotech news site | Luke Timmerman’s gone rogue.
The veteran life sciences reporter, who left Xconomy last year, is back to day-to-day journalism. Except this time, he’s doing it on his own: Timmerman just launched his own biotech site – The Timmerman Report –... |
